Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Assessment of the evolution of fibrinogen plasma level within the first ten days after major trauma in order to determine prevalence of hyperfibrinogenemia (Fg > 4 g/L) and its time to onset.
In this study, investigators daily investigate fibrinogen plasma levels and fibrinogen antigen in severe trauma patients (Injury severity score > 15) within the first ten days. Investigators then modelize hyperfibrinogenemia profiles according to severity of injuries and physiopathologic mechanisms. Finally, investigators determine predisposing risk factors to develop hyperfibrinogenemia and assess the impact of fibrinogen replacement therapy in initial phase of management of major trauma.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Severe trauma patients | Experimental | All severe trauma patients (ISS>15) admitted in our trauma center Blood samples (additional blood tubing) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood samples | Procedure | Investigators analyze hematological parameters with blood sampled daily in severe trauma patients |
|
| Measure | Description | Time Frame |
|---|---|---|
| daily fibrinogen level >4 g/L | the occurrence and delay of fibrinogen level > 4 g/L after major trauma | 10 days |
| Measure | Description | Time Frame |
|---|---|---|
| assessing predisposing risk factors of hyperfibrinogenemia (> 4 g/l) | Initial chock status severity, vascular filling, initial acidose, hypothermia, trauma severity (ISS scores, Sequential Organ Failure Assessment (SOFA), IGS2), numbers and sites of lesions (AIS scores), severity of initial failure of fibrinogene, administration of fibrinogene at initial hemorrhagic phase… | 10 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Pauline PD DERAS, MD | Contact | +334 67 33 82 56 | p-deras@chu-montpellier.fr | |
| Sophie SB BRINGUIER, PharmD | Contact | +334 67 33 82 56 | s-bringuierbranchereau@chu-montpellier.fr |
| Name | Affiliation | Role |
|---|---|---|
| Pauline PD DERAS, MD | Regional Trauma Center, Department of Anesthesiology and critical care, Lapeyronie University Hospital, Montpellier | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Anesthesiology and critical care, Lapeyronie University Hospital | Recruiting | Montpellier | 34295 | France |
Not provided
| ID | Term |
|---|---|
| D014947 | Wounds and Injuries |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| plasmatic fibrinogen level evolution | 10 days |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |